Expert Insights on COVID-19 Prophylaxis in Patients with Multiple Sclerosis and Related Disorders

Posttest

Expert Insights on COVID-19 Prophylaxis in Patients with Multiple Sclerosis and Related Disorders

Please choose the best answer for the questions below, then click the button at the bottom to proceed.

Items marked with * require a response.
Email*
1. Which of the following best describes the use of monoclonal antibodies (mAbs) for COVID-19 pre-exposure prophylaxis?*
- mAbs bind to a conserved region on the spike protein, and efficacy remains consistent against the different SARS-CoV-2 variants
- They should be considered routinely for people with multiple sclerosis (pwMS)
- They provide “passive immunity”—the immune system is not involved in creating antibodies that act against the virus
- They provide “active immunity” by triggering the production of downstream antibodies that actively prevent SARS-CoV-2 infection
2. Which of the following statements about mAbs with U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for COVID-19 pre-exposure prophylaxis is true, as of May 2024?*
- Sipavibart lost its EUA due to waning efficacy
- Pemivibart is currently the only agent with EUA for pre-exposure prophylaxis
- Cilgavimab has a black box warning due to rare cases of anaphylaxis following infusion
- Combination therapy with tixagevimab/cilgavimab has EUA
3. Which of the following statements about the anti–SARS-CoV-2 mAbs pemivibart and sipavibart is correct?*
- The phase 3 trials of both agents have the same primary endpoint, which is the development of symptomatic COVID-19
- Both agents are being studied for efficacy against current newer SARS-CoV-2 variants
- Both agents are being studied in populations enriched for pwMS and related disorders
- Immunobridging is being used to establish efficacy of both agents
4. Which of the following patients with MS is most likely to benefit from COVID-19 pre-exposure prophylaxis, based on evidence and an individualized assessment of risk factors?*
- A 50-year-old White man with hypertension who is treated with anti-CD20 therapy and who received his most recent COVID-19 vaccine 4 months ago
- A 50-year-old Black woman with hypertension who is receiving anti-CD20 therapy and who received her most recent COVID-19 vaccine 1 week ago
- A 30-year-old pregnant Black woman whose last dose of disease-modifying therapy (DMT) was 7 months ago and whose last COVID-19 vaccine was 2 months ago
- A 30-year-old Hispanic man who is treated with sphingosine-1-phosphate (S1P) receptor modulator therapy and who received his last COVID-19 vaccine 4 months ago
5. Which of the following recommendations is supported by the National MS Society (NMSS)?*
- Pre-exposure prophylaxis is an alternative to COVID-19 vaccination in pwMS
- Clinicians should consider all patients with MS as immunocompromised when assessing risk
- Pemivibart is contraindicated in patients receiving high-dose steroids
- Patients with MS taking alemtuzumab may benefit from pre-exposure prophylaxis

PosttestExpert Insights on COVID-19 Prophylaxis in Patients with Multiple Sclerosis and Related Disorders

Posttest

Expert Insights on COVID-19 Prophylaxis in Patients with Multiple Sclerosis and Related Disorders